Byhealth Co Ltd

Byhealth maintains a strong liquidity position with a current ratio of 2.95, indicating the company can cover its short-term obligations more than two and a half times over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The price-to-book ratio of 1.53 suggests the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. Profitability metrics show a return on equity (ROE) of 7.04% and a return on assets (ROA) of 5.59%, both below the typical thresholds for high-performing food processing firms. The company's gross profit margin is 67.6%, which is strong, but its operating margin of 15.5% is moderate, suggesting room for improvement in cost control. Geographically, Byhealth's revenue is concentrated in a single market, with no disclosed international operations, which increases exposure to local economic and regulatory risks. The company's revenue concentration in a single region is a key risk factor, as it limits diversification and resilience to regional downturns. Looking ahead, Byhealth is projected to grow revenue by 8.2% in the current fiscal year and 5.4% in the next, based on analyst estimates. The company's capital expenditure of -133.4 million CNY indicates a reduction in investment, which may signal a focus on cost optimization rather than expansion. The company's free cash flow of 360.8 million CNY supports dividend sustainability and debt reduction. The company faces moderate liquidity risk due to its negative net cash position and a debt-to-equity ratio of 0.09, which is low but not negligible. Analysts have assigned a mean recommendation of 2.00, indicating a generally positive outlook, with a mean price target of 12.82 CNY and a median of 13.21 CNY. The low dilution risk is supported by the absence of recent share issuance and no near-term pressure for further dilution. Recent filings and transcripts indicate a focus on cost optimization and market expansion within its core region. The company has not disclosed any major regulatory or geopolitical risks, but its exposure to a single market remains a concern.